Displaying 3941 - 3960 of 4745
Nestle Holdings, Inc., and Ralston Purina Company
Nestle settled antitrust charges that its $10.3 billion proposed acquisition of Ralston Purina Company would substantially lessen competition in the United States market for dry cat food through the elimination of direct competition between the two firms and increase the likelihood that the combined firm could unilaterally exercise market power. The order requires the divestiture of Ralston's Meow Mix and Alley Cat brands to J.W. Childs Equity Partners II,L.P.
Valassis Communications, Inc., In the Matter of
Valassis, a leading producer of free-standing newspaper inserts in the United States, has settled charges that it violated Section 5 of the FTC Act by attempting to collude with News America Marketing, its only rival, to eliminate competition between the two companies. During a conference call with industry analysts, a Valassis executive invited NewsAmerica to join in a scheme to allocate customers and fix prices in order to end an ongoing price war between the two companies. Under the consent order settling the FTC’s complaint, Valassis is barred from engaging in or inviting collusive agreements with other publishers or attempting to collude with its competitors.
Procter & Gamble Company and The Gillette Company, In the Matter of
Bureau of Competition Issues FY 2005 Summary of Pharmaceutical Company Settlement Agreements
Allergan, Inc., and Inamed Corporation, In the Matter of
The consent order requires that Allergan and Inamed divest the rights to develop and distribute Reloxin, a potential Botox rival, to settle charges that Allergan’s $3.2 billion purchase of Inamed would reduce competition and force consumers to pay higher prices for botulinum toxin type A products. Under the terms of the FTC settlement, the companies will return the development and distribution rights to Reloxin to Ipsen Ltd., its U.K.- based manufacturer.
Commission Approves Final Consent Order in Matter of Allergan/Inamed
Maintaining Competition, FTC Allows Fresenius $3.5 Billion Deal to Buy Rival Dialysis Provider Renal Care Group
FTC Proposes Study of Competitive Impacts of Authorized Generic Drugs
Hospitals Plan for Collective Bargaining of Physicians Fees Likely Would Violate Federal Laws, FTC Staff Says
Health Care Alliance of Laredo, L.C., In the Matter of
Preserving Competition, FTC Requires Divestiture Before Allowing Allergans Acquisition of Inamed
Teva Pharmaceutical Industries Ltd. and IVAX Corporation, In the Matter of
The consent order allowed Teva to acquire IVAX Corporation, provided the companies sell the rights and assets needed to manufacture and market 15 generic pharmaceutical products. Among the drugs sold were several forms of generic amoxicillin and amoxicillin clavulanate potassium that are widely used in the United States.
FTC Staff Files Comments on New Jerseys Proposed Advertising Guideline 4; Commission Finalizes Teva/Ivax Consent Order
Texas Doctors' IPA Agrees to Settle Price Fixing Charges
Davita Inc. Submits Petition for Approval of Proposed Divestiture; FTC Submits Budget Request and Performance Plans to Congress
Prepared Statement of the Federal Trade Commission On Committee on the Judiciary, United States Senate
FTC Provides Senate Testimony on Initiatives to Protect Competition in the U.S. Petroleum Industry
Displaying 3941 - 3960 of 4745